AIDP announces that Magtein magnesium l-threonate, a patented compound for cognitive health, has received a Letter of No Objection from the Food and Drug Administration, confirming its GRAS (generally regarded as safe) designation. This milestone means that using Magtein in selected food categories at a level of up to 0.12 percent.

Magtein™ magnesium l-threonate is a patented, natural ingredient discovered by MIT professors searching for novel neurodegenerative disease treatments. For this reason, Magtein was extensively studied in cell culture, in animal studies for its mechanisms of action, its effects on brain function, as well as its safety. These results are published in prestigious neurological journals, including Neuron, and supported by top neurological scientists in the world, including Nobel Prize winners.

One reason Magtein has generated so much interest from consumers is its unique mechanism of action: It restores the neural cells to their healthy, youthful conditions by blocking background signal activation, while many other brain ingredients/drugs continue stimulating cells. Recently, a human clinical study using Magtein was performed and preliminary results indicate a significant improvement in memory and cognition.

“Receiving a GRAS designation from the FDA is a huge step for Magtein,” says Kathy Lund, vice president of marketing and business development at AIDP. “It allows us to move beyond our current market in dietary supplements, into the massive food and drink manufacturing industry. Consumers will now potentially be able to get a wide variety of foods, from baked goods to beverages to processed juices and soups, containing Magtein, and reap the many health benefits of this form of magnesium.”